Back to Search Start Over

Minocycline decreases CD36 and increases CD44 in LPS-induced microglia.

Authors :
Hashemi-Monfared A
Firouzi M
Bahrami Z
Zahednasab H
Harirchian MH
Source :
Journal of neuroimmunology [J Neuroimmunol] 2018 Apr 15; Vol. 317, pp. 95-99. Date of Electronic Publication: 2018 Feb 01.
Publication Year :
2018

Abstract

Microglia are the resident macrophages patrolling the central nervous system (CNS) to find dangerous signals and infectious agents mediating catastrophic cascades resulting in neuronal degeneration. Their morphological and biochemical properties made them enable to swift activation in response to neural insults and site-directed phagocytosis. Beside of beneficial roles in homeostasis of the brain and spinal cord, microglia can be participating in neuronal destruction and propagation of inflammation when they are unregulated or hyper-activated. A large body of research indicates that various cluster of differentiations (CDs) contribute to flame/quench the inflammatory processes occurred in immune system. In this study, we investigated the expression of CD36 and CD44 in LPS-activated primary rat microglia in response to treatment of minocycline at the levels of protein and gene using flow cytometry and real-time PCR, respectively. The results showed that minocycline decreased the expression of CD36 in cells treated with minocycline with respect to cells treated with LPS. Inversely, the expression of CD44 was increased in cells treated with minocycline in comparison to LPS-induced microglia. It seems that minocycline can modulate the expression of CDs involved in inflammatory reactions and enrich the armamentarium of therapeutic agents used for the treatment of neuroinflammatory and neurodegenerative disorders.<br /> (Copyright © 2018. Published by Elsevier B.V.)

Details

Language :
English
ISSN :
1872-8421
Volume :
317
Database :
MEDLINE
Journal :
Journal of neuroimmunology
Publication Type :
Academic Journal
Accession number :
29395319
Full Text :
https://doi.org/10.1016/j.jneuroim.2018.01.010